Welcome to our dedicated page for Venus Concept SEC filings (Ticker: VERO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the numbers behind Venus Concept’s subscription-driven business? Investors usually dive into the 10-K annual report to see how many aesthetic systems were placed, how deferred revenue and device receivables move, and whether new FDA clearances expand the pipeline. Others head straight for the 10-Q quarterly earnings report to track cash burn and covenant compliance, or monitor 8-K material events for financing updates. Finding these details fast is the challenge.
Stock Titan solves it with AI-powered summaries that translate complex accounting into clear language. Open any filing and our platform highlights subscription revenue recognition, R&D spend, and global approval milestones in seconds. Real-time alerts surface every Venus Concept insider trading Form 4 transaction, while concise notes explain what each trade may signal. You’ll also get instant access to:
- Venus Concept quarterly earnings report 10-Q filing with side-by-side AI insights
- Venus Concept executive stock transactions Form 4 shown in real time
- Proxy statement executive compensation tables, distilled for quick comparison
- 8-K material events explained so you understand financing and regulatory news
Whether you’re asking, “How is subscription revenue booked?” or “Where can I find Venus Concept SEC filings explained simply?”, you’ll find the answer here. Our coverage spans every form—from annual report 10-K simplified to insider buying alerts—updated the moment EDGAR posts. Stop scrolling through hundreds of pages; let our AI surface the insights that drive decisions.
Schedule 13D/A (Amendment No. 8) – Venus Concept Inc. (NASDAQ: VERO)
The filing updates the ownership disclosure of several Madryn-affiliated investment vehicles following shareholder approval on 25 June 2025 that lifts Nasdaq convertibility limits on the Company’s Series X & Y Preferred Stock and 2025 Convertible Notes. The approval now permits those securities to be converted into common stock, potentially increasing the Company’s outstanding share count.
Reporting Persons & Ownership
- Madryn Asset Management, LP (investment adviser) – 10,891,951 shares held jointly; 85.5 % of outstanding common stock; shared voting & dispositive power.
- Madryn Health Partners, LP – 4,029,512 shares; 31.6 % of class.
- Madryn Health Partners (Cayman Master), LP – 6,862,439 shares; 53.9 % of class.
- Madryn Health Advisors, LP (general partner) – mirrors total 10,891,951-share position.
No individual reporting person has sole voting or dispositive power; all authority is shared among the Madryn entities. The filing confirms that none of the Reporting Persons or their principals have faced criminal or civil securities violations in the past five years.
Key Context
- The Madryn entities first financed Venus Concept through a 2016 credit agreement and subsequently received equity and equity-linked instruments that converted at the time of the 2019 Restoration Robotics merger.
- The present amendment does not record additional share purchases or sales but refreshes disclosure to reflect the newly permitted convertibility of existing preferred stock and notes.
- The Madryn group’s aggregate stake establishes effective control of Venus Concept, substantially reducing the public float and limiting minority influence.
Investors should monitor forthcoming conversions, as issuance of common shares underlying the Series X, Series Y and 2025 Notes could materially alter the Company’s capital structure and public float.
Venus Concept (Nasdaq: VERO) filed an 8-K detailing the June 25, 2025 Annual & Special Meeting results.
Key outcomes:
- Shareholders authorized the issuance of up to 11.3 million common shares upon conversion of existing Series Y, Series X, Senior Convertible Preferred Stock and 2025 secured notes.
- All three Class II directors—Louise Lacchin, Anthony Natale M.D. and Stanley Tyler Hollmig M.D.—were re-elected.
- MNP LLP was ratified as independent auditor for FY 2025.
The approvals eliminate contractual share-cap restrictions, enabling conversions that could materially expand the public float while extinguishing preferred obligations and related cash interest. No other material items were reported.
Venus Concept Inc. (Nasdaq: VERO) filed a Form S-1 with the SEC on June 20, 2025 to register the resale of up to 899,870 common shares issuable upon exercise of outstanding warrants. The filing is solely for existing holders; the company itself is not selling shares and will receive no proceeds from any subsequent sales.
The warrants were issued in a previously completed registered direct offering and consist of:
- 869,440 warrants held by participating institutional investors, and
- 30,430 warrants granted to the placement agent as compensation.
Shares may be sold by the holders through ordinary brokerage transactions or other permitted methods at market, fixed, or negotiated prices. All brokerage costs will be borne by the selling stockholders, while Venus Concept will cover registration expenses.
Key filing details:
- Filing type: Form S-1 (resale registration).
- Share listing: Nasdaq Capital Market, ticker VERO.
- Last reported share price (16 Jun 2025): $2.48.
- The company is classified as a non-accelerated filer and smaller reporting company.
The prospectus warns prospective investors to review the incorporated risk factors and emphasizes that market and industry data are based on third-party sources. Because the registration enables nearly 0.9 million additional shares to become freely tradable without raising capital for Venus Concept, investors should consider potential dilution and market-supply pressure once the warrants are exercised.
FAQ
What is the current stock price of Venus Concept (VERO)?
What is the market cap of Venus Concept (VERO)?
